Compare QTRX & DHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QTRX | DHF |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Finance Companies |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.0M | 176.2M |
| IPO Year | 2017 | 1998 |
| Metric | QTRX | DHF |
|---|---|---|
| Price | $3.33 | $2.40 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 185.0K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $37,632,000.00 | N/A |
| Revenue This Year | $25.49 | N/A |
| Revenue Next Year | $10.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 64.52 | N/A |
| 52 Week Low | $2.40 | $2.33 |
| 52 Week High | $8.77 | $2.63 |
| Indicator | QTRX | DHF |
|---|---|---|
| Relative Strength Index (RSI) | 55.09 | 43.44 |
| Support Level | $3.11 | $2.38 |
| Resistance Level | $3.81 | $2.47 |
| Average True Range (ATR) | 0.34 | 0.02 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 40.44 | 0.00 |
Quanterix Corp is a life sciences company accelerating biomarker breakthroughs from discovery to diagnostics using ultra-sensitive translational research and spatial biology instruments, consumables, and services. The company sells proprietary instruments and related consumables to research laboratories, contract research organizations (CROs), academic institutions, and bio-pharmaceutical companies, and provides contract research services and clinical laboratory testing services, including four Laboratory Developed Tests (LDTs), through its Accelerator Laboratory. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, and SP-X Imaging and Analysis System. Geographically, it operates in North America, EMEA, and the Asia Pacific.
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. The fund invests predominantly in fixed-income securities of below-investment-grade credit quality.